LLY News and Press, Eli Lilly and Company From 12/05/23

2023-12-05 05:53:10 ET Vanda Pharma ( NASDAQ: VNDA ) shares jumped 19% premarket on Tuesday as the FDA accepted the new drug application (NDA) for tradipitant, an experimental drug for the treatment of gastroparesis. Tradipitant is a neurokinin 1 antagonist licensed by V...

2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...

2023-12-04 11:54:15 ET More on Viking Therapeutics Viking Therapeutics, Inc. (VKTX) Q3 2023 - Earnings Call Transcript Viking's Incretin Mimetic Data Fails To Move Stock - Has Mr. Market Moved On? Pfizer hits new 52-week low after weight loss setback Viking T...

2023-12-04 10:54:59 ET More on 89bio 89bio's Low Price Presents An Opportunity 89bio: Risk And Reward Balance In NASH Therapeutics 89bio gains FDA breakthrough status for NASH candidate Seeking Alpha’s Quant Rating on 89bio Historical earnings ...

2023-12-04 09:15:50 ET Summary The Eaton Vance Enhanced Equity Income Fund II offers a reasonably high level of current income without sacrificing potential stock appreciation. The fund has a yield of 7.47%, lower than other funds with a similar strategy, reducing the appeal of th...

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 PR Newswire INDIANAPOLIS , Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and o...

2023-12-04 05:44:22 ET Roche ( OTCQX:RHHBY ) announced on Monday a deal to acquire U.S. biotechnology company Carmot Therapeutics for USD 2.7B in cash at closing. Based in Berkeley, California, Carmot specializes in obesity drugs, with a broad pipeline of therapeutics, including thr...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-12-03 07:10:23 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...

2023-12-03 06:54:00 ET Nike 's "Just Do It" tagline usually isn't great advice for investors. It's smart to conduct solid research on a stock before buying. That said, some outliers are so promising that spending a lot of time in analysis isn't so necessary. Three Motley Fool contri...